Ahmet B. Gungor

The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab–Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center

Mohanad Al‐Obaidi, Ahmet B. Gungor, Sandra Kurtin et al. · The American Journal of Medicine · 2022 · 48 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +9

Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection

Mohanad Al‐Obaidi, Ahmet B. Gungor, Saman Nematollahi et al. · Open Forum Infectious Diseases · 2022 · 16 citations · Full text

Pharmacy, Immunology, Infectious Diseases +13

The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era

Mohanad Al‐Obaidi, Ahmet B. Gungor, Sangeetha Murugapandian et al. · The American Journal of Medicine · 2023 · 15 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era

Srilekha Sridhara, Ahmet B. Gungor, Halil Erol et al. · PLoS ONE · 2023 · 10 citations · Full text

Life Sciences, Immunology, Infectious Diseases +16